Quarterly ResultMay 5, 2026, 06:42 AM
SOPHiA GENETICS Q1 Revenue Up 22% to $21.7M; Net Loss $19.3M
AI Summary
SOPHiA GENETICS reported a 22% year-over-year revenue increase to $21.7 million for the first quarter of 2026, driven by strong demand for its platform and new applications. Despite an 11% increase in IFRS net loss to $19.3 million, the company saw a 3% improvement in Adjusted EBITDA loss to $9.2 million. Operational highlights include a record 108,000 genomic analyses performed and an increase in Net Dollar Retention to 117%.
Key Highlights
- Revenue increased 22% year-over-year to $21.7 million for Q1 2026.
- IFRS net loss was $19.3 million, an 11% increase year-over-year.
- Adjusted EBITDA loss improved 3% year-over-year to $9.2 million.
- Performed a record 108,000 genomic analyses on SOPHiA DDMTM, up 16% year-over-year.
- Net Dollar Retention increased to 117% in Q1 2026, up from 103% in Q1 2025.
- Signed 18 new core genomic customers and reached 537 core genomics customers.
- Received $14.5 million in net proceeds from an at-the-market (ATM) offering.
- Basic and diluted loss per share was $(0.27) for Q1 2026, compared to $(0.26) in Q1 2025.